Abstract:Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in awide variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD28 pathway, leading to inhibition of T cell proliferation, activation, cytokine production, altered metabolism and cytotoxic T lymphocytes (CTLs) killer functions, and eventual death of activated T cells. Bodies evolve coinhibitory pathways controllingTcell response magnitude and duration to limit tissue damage and maintain self-tolerance. However, tumor cells hijack these inhibitory pathways to escape host immune surveillance by overexpression of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the "primary" activation of multiple oncogenic signaling and the "secondary" induction by inflammatory factors such as IFN-.. Clinically, antibodies targeting PD-1/PD-L1 reinvigorate the "exhausted" T cells in TME and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as melanoma, lymphoma, and mismatch-repair deficient tumors. Nevertheless, most patients are still refractory to anti-PD-1/PD-L1 therapy. Identifying the predictive biomarkers and design rational PD-1-based combination therapy become the priorities in cancer immunotherapy. PD-L1 expression, cytotoxic T lymphocytes infiltration, and tumor mutation burden (TMB) are generally considered as the most important factors affecting the effectiveness of PD-1/PD-L1 blockade. The revolution in cancer immunotherapy achieved by PD-1/PD-L1 blockade offers the paradigm for scientific translation from bench to bedside. The next decades will without doubt witness the renaissance of immunotherapy.

Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.

The Nuclear Transportation of PD-L1 and the Function in Tumor Immunity and Progression

PD-1/PD-L1 Signaling Pathway and Its Anti-Tumor Effect in Lymphoma——Review

Expression of PD-L1 in lymphoma and its effect on lymphoma proliferation and chemotherapy resistance]

PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.

Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells

[Research Advances on Programmed Cell Death Receptor-1 Antibody in the Treatment of Lymphoma--Review]

Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art

Expression and Clinical Value of Programmed Cell Death-Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma: a Retrospective Study

The emerging roles of PD-L1 subcellular localization in tumor immune evasion

Advances of PD-1/PD-L1 inhibitors in tumor immunotherapy

PD-1/PD-Ls SignaI Pathway and the Appiication of Anti-Pd-1/pd-ls Antibodies in Cancer Therapy

Programmed cell death-ligand 2: new insights in cancer

Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

PD-L1 Over-Expression is Driven by B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

The Role of PD-1 and PD-L1 in T-cell Immune Suppression in Patients with Hematological Malignancies

Targeting PD-1/PD-L1 in tumor immunotherapy: Mechanisms and interactions with host growth regulatory pathways

Progress of research on PD-1/PD-L1 in leukemia